Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 1/2 1Phase 1 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Biliary Tract Neoplasms 2Metastatic HER2-positive Breast Cancer 1Gallbladder Neoplasms 1Cholangiocarcinoma 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 52Fluorouracil 52Magnetic Resonance Spectroscopy 50Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 44Leucovorin 39Drug Therapy 39Irinotecan 37Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Letrozole 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × zanidatamab × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06435429 2026-02-10

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
550 enrolled
Breast

Metastatic HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡